COVI,关于COVI的所有信息
-
世界最新:先声药业:新冠新药上市申请获受理
南方财经1月16日电,先声药业宣布:与中国科学院上海药物研究所、武汉病毒研究所联合开发的创新药先诺欣?(先诺特韦片 利托那韦片组合包装)新
-
China's COVID response in numbers: "Lives for lives"!
ChinasparesnoefforttopreventandtreatseverecasesofCOVID-19withbetter
-
天天看热讯:China enters a new stage of COVID-19 response
Chinareleasedthe10thCOVID-19preventionandcontrolprotocolJan 7,outlini
-
天天速讯:Posters: China's fight against COVID with solidarity, tenacity and mutual support
- "GohomefortheSpringFestival "isacommonaspirationofhundredsofmillio
-
环球热消息:Poster: Foreign diplomats in China view COVID response policy adjustment timely, necessary
ChinahasrecentlytakentheinitiativetorefineitsCOVIDresponsemeasures B
-
世界快看:Timing of China's COVID response shift related to elderly vaccination: expert
(ECNS)--ThereasonthatChinachosetoadjustitsCOVID-19responsemeasuresa
-
环球视点!China enters new phase of COVID response
0:00 2:26*Consideringfactorsincludingthedevelopmentoftheepidemic,thein
-
世界简讯:China Focus: China strives for vitality after COVID management downgrade
InboundpassengersarriveatShanghaiPudongInternationalAirportineastChina
-
Defaming China's optimization in COVID-19 response exposes political prejudices of the West
China,enhancingtheconstructionandcoordinationofitsmedicalresources,has
-
环球滚动:China's economic performance amid COVID-19 battle
Editor snote:Overthepastthreeyears,Chinahasbeenworkingtocoordinateit
-
【世界聚看点】可能诱发心肌炎,“阳过”和“阳康”能锻炼吗?
最近,不少朋友在社交平台分享了自己的“阳过”和“阳康”经历第四天了,终于退烧了 一场感冒,一家人都挺过来了 1何为心肌炎。然而
-
世界快看点丨China to crack down on anti-COVID drug related violations
PhotoshowsCOVID-19antigenrapidtestkits(Photo:ChinaNewsService ZhangH
-
全球微动态丨CAN008治疗COVID-19重症显疗效,北海康成潜力大
随着防疫政策不断优化放开,国内迎来疫情感染高峰、重症高峰,再加上病毒株持续变异,人们正面临着医疗资源紧缺、有限的治疗药物、紧张的供求
-
快讯:Putting people first central to China's COVID response
AnelderlymanreceivesaCOVID-19vaccineshotinZhengzhou,Henanprovince,on
-
全球观点:GLOBALink | China's optimized COVID-19 response conducive to global tourism: Pakistani official
ISLAMABAD,Jan 3(Xinhua)--China snewlyadjustedCOVID-19responsethatlift
-
全球观天下!君实生物:VV116已完成一项对比PAXLOVID的轻至中度COVID-19患者早期治疗的III期临床研究
实生物公告,公司控股子公司君拓生物与旺山旺水合作开发的口服核苷类抗SARS-CoV-2药物VV116片(项目代号:JT001 VV116,“VV116”)已完成
-
天天热讯:GLOBALink | Vlog: How's life in Beijing amid refining of COVID-19 response
Bustlingtrafficbackonroads,dinerscrowdinginrestaurants,touristdestinat
-
全球速递!New dawn breaks in battle against COVID-19
LIMIN CHINADAILYFocusnowonvulnerablegroupsandpatientsinseriousconditi
-
China Focus: China releases details of COVID-19 management shift
BEIJING,Dec 28(Xinhua)--Chinahasannouncedthatitwillbedowngradingits
-
环球观焦点:罗氏(RHHBF.US)Actemra获FDA批准用于COVID-19
格隆汇12月22日丨罗氏的Actemra(tocilizumab)成为美国FDA批准的首个用于COVID-19的单克隆抗体。自2021年6月以来,该药物已通过紧急使用授权(EU